Intervention on gut microbiota may change the strategy for management of colorectal cancer.
Sedigheh Taghinezhad-SAmir Hossein MohseniXiangsheng FuPublished in: Journal of gastroenterology and hepatology (2021)
Dysbiosis in the gut microbiota composition due to environmental or genetic variations can disrupt the immune system and may promote several diseases such as colorectal cancer (CRC). Gut microbiota can alter the toxicity and efficiency of an extensive range of CRC treatment methods, especially surgery, chemotherapy, radiotherapy, and immunotherapy. The recent scientific evidence suggested that gut microbiota modulation exhibits an essential positive influence on inhibition and treatment of CRC. The literature survey revealed that modulating the gut microbiota composition by probiotics, prebiotics, and diets protects CRC patients from treatment-associated adverse effects. This review summarizes the recent advancements in the association between interventions on gut microbiota and CRC to provide innovative strategies for enhancing the safety and efficiency of CRC therapy.
Keyphrases
- systematic review
- end stage renal disease
- randomized controlled trial
- physical activity
- early stage
- squamous cell carcinoma
- radiation therapy
- ejection fraction
- peritoneal dialysis
- prognostic factors
- locally advanced
- genome wide
- mesenchymal stem cells
- dna methylation
- risk assessment
- smoking cessation
- replacement therapy
- patient reported outcomes
- cross sectional